Critical evaluation of 1H NMR metabonomics of serum as a methodology for disease risk assessment and diagnostics
暂无分享,去创建一个
[1] Doris M Jacobs,et al. Probing gender-specific metabolism differences in humans by nuclear magnetic resonance-based metabonomics. , 2006, Analytical biochemistry.
[2] E Holmes,et al. Chemometric contributions to the evolution of metabonomics: mathematical solutions to characterising and interpreting complex biological NMR spectra. , 2002, The Analyst.
[3] D W Bennett,et al. Quantification of plasma lipoproteins by proton nuclear magnetic resonance spectroscopy. , 1991, Clinical chemistry.
[4] M. Dyrby,et al. Quantification of lipoprotein subfractions using 1H-NMR and chemometrics , 2003 .
[5] Kimmo Kaski,et al. Characterization and molecular detection of atherothrombosis by magnetic resonance—potential tools for individual risk assessment and diagnostics , 2006, Annals of medicine.
[6] R. Koopman,et al. Predicting coronary heart disease risk using multiple lipid measures. , 2005, The American journal of cardiology.
[7] D. Levy,et al. Low-Grade Albuminuria and Incidence of Cardiovascular Disease Events in Nonhypertensive and Nondiabetic Individuals: The Framingham Heart Study , 2005, Circulation.
[8] Johan Trygg,et al. Chemometrics in metabonomics. , 2007, Journal of proteome research.
[9] Jimmy D Bell,et al. Factors affecting 1h NMR spectra of blood plasma: cancer, diet and freezing , 1988, NMR in biomedicine.
[10] D. Arnett,et al. Comparison of ultracentrifugation and nuclear magnetic resonance spectroscopy in the quantification of triglyceride-rich lipoproteins after an oral fat load. , 2004, Clinical chemistry.
[11] Moyses Szklo,et al. LDL particle subclasses, LDL particle size, and carotid atherosclerosis in the Multi-Ethnic Study of Atherosclerosis (MESA). , 2007, Atherosclerosis.
[12] Elaine Holmes,et al. Metabolic profiling of plasma from discordant schizophrenia twins: correlation between lipid signals and global functioning in female schizophrenia patients. , 2006, Journal of proteome research.
[13] I. Wilson,et al. Metabonomics, dietary influences and cultural differences: a 1H NMR-based study of urine samples obtained from healthy British and Swedish subjects. , 2004, Journal of pharmaceutical and biomedical analysis.
[14] John C Lindon,et al. Use of relaxation-edited one-dimensional and two dimensional nuclear magnetic resonance spectroscopy to improve detection of small metabolites in blood plasma. , 2004, Analytical biochemistry.
[15] Elaine Holmes,et al. The challenges of modeling mammalian biocomplexity , 2004, Nature Biotechnology.
[16] S. Soedamah-Muthu,et al. Trends in hypertension management in Type I diabetes across Europe, 1989/1990 – 1997/1999 , 2003, Diabetologia.
[17] Aki Vehtari,et al. A novel Bayesian approach to quantify clinical variables and to determine their spectroscopic counterparts in 1H NMR metabonomic data , 2007, BMC Bioinformatics.
[18] Rasmus Bro,et al. Analysis of lipoproteins using 2D diffusion-edited NMR spectroscopy and multi-way chemometrics , 2005 .
[19] P J Sadler,et al. Proton-nuclear-magnetic-resonance studies of serum, plasma and urine from fasting normal and diabetic subjects. , 1984, The Biochemical journal.
[20] G. Hitman,et al. The effect of atorvastatin on serum lipids, lipoproteins and NMR spectroscopy defined lipoprotein subclasses in type 2 diabetic patients with ischaemic heart disease. , 2003, Atherosclerosis.
[21] J. M. Carr,et al. Detection of malignant tumors. Water-suppressed proton nuclear magnetic resonance spectroscopy of plasma. , 1986, The New England journal of medicine.
[22] U. Engelke,et al. Proton nuclear magnetic resonance spectroscopy of body fluids in the field of inborn errors of metabolism , 2003, Annals of clinical biochemistry.
[23] Jimmy D Bell,et al. Quantification of biomedical NMR data using artificial neural network analysis: Lipoprotein lipid profiles from 1H NMR data of human plasma , 1995, NMR in biomedicine.
[24] Anthony F. P. Nash,et al. A 1H NMR-based metabonomic study of urine and plasma samples obtained from healthy human subjects. , 2003, Journal of pharmaceutical and biomedical analysis.
[25] M. Taskinen,et al. Lipoprotein subclasses and particle sizes and their relationship with coronary artery calcification in men and women with and without type 1 diabetes. , 2002, Diabetes.
[26] Alan Hutson,et al. Detection of epithelial ovarian cancer using 1H‐NMR‐based metabonomics , 2005, International journal of cancer.
[27] N. Serkova,et al. Pattern recognition and biomarker validation using quantitative 1H-NMR-based metabolomics , 2006, Expert review of molecular diagnostics.
[28] W. Cromwell,et al. Low-density lipoprotein particle number and risk for cardiovascular disease , 2004, Current atherosclerosis reports.
[29] T. Orchard,et al. Lipoprotein subclass measurements by nuclear magnetic resonance spectroscopy improve the prediction of coronary artery disease in Type 1 Diabetes. A prospective report from the Pittsburgh Epidemiology of Diabetes Complications Study , 2003, Diabetologia.
[30] A. Fernie,et al. Metabolite profiling: from diagnostics to systems biology , 2004, Nature Reviews Molecular Cell Biology.
[31] Elaine Holmes,et al. Metabonomics technologies and their applications in physiological monitoring, drug safety assessment and disease diagnosis , 2004, Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals.
[32] J. Nicholson,et al. Application of chemometrics to 1H NMR spectroscopic data to investigate a relationship between human serum metabolic profiles and hypertension. , 2003, The Analyst.
[33] M Ala-Korpela,et al. 1H NMR-based absolute quantitation of human lipoproteins and their lipid contents directly from plasma. , 1994, Journal of lipid research.
[34] R. D'Agostino,et al. Increased Small Low-Density Lipoprotein Particle Number: A Prominent Feature of the Metabolic Syndrome in the Framingham Heart Study , 2005, Circulation.
[35] S. Haffner,et al. Insulin resistance and adiposity influence lipoprotein size and subclass concentrations. Results from the Insulin Resistance Atherosclerosis Study. , 2005, Metabolism: clinical and experimental.
[36] C. Heward,et al. Disparate LDL phenotypic classification among 4 different methods assessing LDL particle characteristics. , 2006, Clinical chemistry.
[37] J. Griffin. The Cinderella story of metabolic profiling: does metabolomics get to go to the functional genomics ball? , 2006, Philosophical Transactions of the Royal Society B: Biological Sciences.
[38] Kimmo Kaski,et al. The inherent accuracy of 1H NMR spectroscopy to quantify plasma lipoproteins is subclass dependent. , 2007, Atherosclerosis.
[39] John C. Lindon,et al. Use of 1H NMR‐determined diffusion coefficients to characterize lipoprotein fractions in human blood plasma , 2002 .
[40] W. Cromwell,et al. Measurement issues related to lipoprotein heterogeneity. , 2002, The American journal of cardiology.
[41] A. Nitenberg,et al. Postprandial endothelial dysfunction: role of glucose, lipids and insulin. , 2006, Diabetes & metabolism.
[42] D. Leibfritz,et al. Visualizing metabolic changes in breast‐cancer tissue using 1H‐NMR spectroscopy and self‐organizing maps , 2003, NMR in biomedicine.
[43] K. Kaski,et al. 1H NMR metabonomics of plasma lipoprotein subclasses: elucidation of metabolic clustering by self‐organising maps , 2007, NMR in biomedicine.
[44] B. Zetter,et al. Cancer biomarkers: knowing the present and predicting the future. , 2005, Future oncology.
[45] V. Fuster,et al. Evolving Concepts in the Triad of Atherosclerosis, Inflammation and Thrombosis , 2004, Journal of Thrombosis and Thrombolysis.
[46] K. Kaski,et al. Diagnosing diabetic nephropathy by 1H NMR metabonomics of serum , 2007, Magnetic Resonance Materials in Physics, Biology and Medicine.
[47] R. Kauppinen,et al. A metabolomics perspective of human brain tumours , 2007, The FEBS journal.
[48] Mika Ala-Korpela,et al. 1H NMR spectroscopy of human blood plasma , 1995 .
[49] T. Bathen,et al. Quantification of plasma lipids and apolipoproteins by use of proton NMR spectroscopy, multivariate and neural network analysis , 2000, NMR in biomedicine.
[50] A. Jenkins,et al. Apolipoprotein C-III protein concentrations and gene polymorphisms in type 1 diabetes: associations with lipoprotein subclasses. , 2004, Metabolism: clinical and experimental.
[51] Nicholas J Wareham,et al. Value of low-density lipoprotein particle number and size as predictors of coronary artery disease in apparently healthy men and women: the EPIC-Norfolk Prospective Population Study. , 2007, Journal of the American College of Cardiology.
[52] P. Valensi,et al. Serum 1H‐nuclear magnetic spectroscopy followed by principal component analysis and hierarchical cluster analysis to demonstrate effects of statins on hyperlipidemic patients , 2005, NMR in biomedicine.
[53] Ian D Wilson,et al. Analytical strategies in metabonomics. , 2007, Journal of proteome research.
[54] T. Lyons,et al. Lipoprotein subclass profiles of hyperlipidemic diabetic mice measured by nuclear magnetic resonance spectroscopy. , 2003, Metabolism: clinical and experimental.
[55] R. Hewer,et al. Applying biofluid 1H NMR-based metabonomic techniques to distinguish between HIV-1 positive/AIDS patients on antiretroviral treatment and HIV-1 negative individuals. , 2006, Journal of pharmaceutical and biomedical analysis.
[56] Julian L Griffin,et al. Metabonomics: NMR spectroscopy and pattern recognition analysis of body fluids and tissues for characterisation of xenobiotic toxicity and disease diagnosis. , 2003, Current opinion in chemical biology.
[57] Christophe Ladroue,et al. Independent component analysis for automated decomposition of in vivo magnetic resonance spectra , 2003, Magnetic resonance in medicine.
[58] Wolfgang Rosenstiel,et al. Neural Networks Evaluating NMR Data: An Approach To Visualize Similarities and Relationships of Sol-Gel Derived Inorganic-Organic and Organometallic Hybrid Polymers1 , 2002, J. Chem. Inf. Comput. Sci..
[59] Markku J. Savolainen,et al. STRUCTURAL CHANGES OF LIPOPROTEIN LIPIDS BY 1H NMR , 1995 .
[60] J. Lindon,et al. Pharmaco-metabonomic phenotyping and personalized drug treatment , 2006, Nature.
[61] R. Krauss,et al. Development of a proton nuclear magnetic resonance spectroscopic method for determining plasma lipoprotein concentrations and subspecies distributions from a single, rapid measurement. , 1992, Clinical chemistry.
[62] Zahi A. Fayad,et al. Molecular, cellular and functional imaging of atherothrombosis , 2004, Nature Reviews Drug Discovery.
[63] John C Lindon,et al. Sample classification based on Bayesian spectral decomposition of metabonomic NMR data sets. , 2004, Analytical chemistry.
[64] Julian L Griffin,et al. Proton NMR analysis of plasma is a weak predictor of coronary artery disease , 2006, Nature Medicine.
[65] D. Lackland,et al. Nuclear magnetic resonance‐determined lipoprotein subclass profile in the DCCT/EDIC cohort: associations with carotid intima‐media thickness , 2006, Diabetic medicine : a journal of the British Diabetic Association.
[66] An NMR blood test for cancer: a critical assessment. , 1989, NMR in biomedicine.
[67] B. Goodfellow,et al. Metabolic characterisation of plasma in juveniles with glycogen storage disease type 1a (GSD1a) by high‐resolution 1H NMR spectroscopy , 2007, NMR in biomedicine.
[68] Elaine Holmes,et al. Impact of analytical bias in metabonomic studies of human blood serum and plasma. , 2006, Analytical chemistry.
[69] J. van der Greef,et al. The role of analytical sciences in medical systems biology. , 2004, Current opinion in chemical biology.
[70] J. Nicholson,et al. Rapid and noninvasive diagnosis of the presence and severity of coronary heart disease using 1H-NMR-based metabonomics , 2002, Nature Medicine.
[71] P. McBride,et al. Should advanced lipoprotein testing be used in clinical practice? , 2006, Nature Clinical Practice Cardiovascular Medicine.
[72] R. Superko. Lipoprotein subclasses and atherosclerosis. , 2001, Frontiers in bioscience : a journal and virtual library.
[73] T. Ebbels,et al. Analytical reproducibility in (1)H NMR-based metabonomic urinalysis. , 2002, Chemical research in toxicology.
[74] J. Trygg,et al. Evaluation of the orthogonal projection on latent structure model limitations caused by chemical shift variability and improved visualization of biomarker changes in 1H NMR spectroscopic metabonomic studies. , 2005, Analytical chemistry.
[75] Robert S Plumb,et al. Statistical heterospectroscopy, an approach to the integrated analysis of NMR and UPLC-MS data sets: application in metabonomic toxicology studies. , 2006, Analytical chemistry.
[76] J. Nicholson. Global systems biology, personalized medicine and molecular epidemiology , 2006, Molecular systems biology.
[77] D. Gauguier,et al. Statistical total correlation spectroscopy: an exploratory approach for latent biomarker identification from metabolic 1H NMR data sets. , 2005, Analytical chemistry.
[78] R. D'Agostino,et al. Sex and age differences in lipoprotein subclasses measured by nuclear magnetic resonance spectroscopy: the Framingham Study. , 2004, Clinical chemistry.
[79] M Ala-Korpela,et al. Application of self‐organizing maps for the detection and classification of human blood plasma lipoprotein lipid profiles on the basis of 1H NMR spectroscopy data , 1998, NMR in biomedicine.
[80] Truman R. Brown,et al. NMR Spectral Quantitation by Principal Component Analysis. , 2002 .
[81] E. Boerwinkle,et al. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I. , 2003, Circulation.
[82] M. Taskinen,et al. Study of agreement between LDL size as measured by nuclear magnetic resonance and gradient gel electrophoresiss⃞s⃞ The online version of this article (available at http://www.jlr.org) contains an additional two tables. Published, JLR Papers in Press, March 1, 2004. DOI 10.1194/jlr.M300395-JLR200 , 2004, Journal of Lipid Research.
[83] A. Jenkins,et al. Effects of insulin resistance and type 2 diabetes on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance. , 2003, Diabetes.
[84] J. Pulkkinen,et al. Independent component analysis to proton spectroscopic imaging data of human brain tumours. , 2005, European journal of radiology.
[85] Ken Williams,et al. Nuclear Magnetic Resonance Lipoprotein Abnormalities in Prediabetic Subjects in the Insulin Resistance Atherosclerosis Study , 2005, Circulation.
[86] S. Soedamah-Muthu,et al. Trends in hypertension management in Type I diabetes across Europe, 1989/1990 – 1997/1999 , 2002, Diabetologia.
[87] Mattias Rantalainen,et al. Statistical correlation and projection methods for improved information recovery from diffusion-edited NMR spectra of biological samples. , 2007, Analytical chemistry.
[88] J. Otvos,et al. Measurement of lipoprotein subclass profiles by nuclear magnetic resonance spectroscopy. , 2002, Clinical laboratory.
[89] Jimmy D Bell,et al. 1H NMR studies of human blood plasma Assignment of resonances for lipoproteins , 1987, FEBS letters.
[90] D. Lackland,et al. Serum lipoproteins in the diabetes control and complications trial/epidemiology of diabetes intervention and complications cohort: associations with gender and glycemia. , 2003, Diabetes care.
[91] E. Dow,et al. Automated analysis of proton NMR spectra from combinatorial rapid parallel synthesis using self-organizing maps. , 2002, Journal of combinatorial chemistry.
[92] W. Cromwell,et al. Lipoprotein particle analysis by nuclear magnetic resonance spectroscopy. , 2006, Clinics in laboratory medicine.
[93] J. Otvos,et al. Effect of orlistat on postprandial lipemia, NMR lipoprotein subclass profiles and particle size. , 2005, Atherosclerosis.
[94] D. Lackland,et al. Diabetic retinopathy and serum lipoprotein subclasses in the DCCT/EDIC cohort. , 2004, Investigative ophthalmology & visual science.
[95] Søren Balling Engelsen,et al. Quantification of lipoprotein subclasses by proton nuclear magnetic resonance-based partial least-squares regression models. , 2005, Clinical chemistry.
[96] I. Wilson,et al. Understanding 'Global' Systems Biology: Metabonomics and the Continuum of Metabolism , 2003, Nature Reviews Drug Discovery.
[97] Brian C Sweatman,et al. Optimisation of collection, storage and preparation of rat plasma for 1H NMR spectroscopic analysis in toxicology studies to determine inherent variation in biochemical profiles. , 2002, Journal of pharmaceutical and biomedical analysis.